1 – 100 of 177
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
(
- Contribution to journal › Letter
-
Mark
MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma : the Nordic Lymphoma Group MCL7 VALERIA trial
(
- Contribution to journal › Article
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
(
- Contribution to journal › Article
-
Mark
Tattoos as a risk factor for malignant lymphoma: a population-based case–control study
(
- Contribution to journal › Article
-
Mark
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE) : a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
(
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
(
- Contribution to journal › Article
-
Mark
Primary central nervous system lymphomas : EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
(
- Contribution to journal › Article
-
Mark
The National Swedish Lymphoma Register – a systematic validation of data quality
(
- Contribution to journal › Article
- 2023
-
Mark
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high dose chemotherapy independent of MIPI and complement established high-risk factors
(
- Contribution to journal › Article
-
Mark
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe : The SCHOLAR-2 retrospective chart review study
(
- Contribution to journal › Article
-
Mark
Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation
(
- Contribution to journal › Article
-
Mark
Exploring new prognostic biomarkers in Mantle Cell Lymphoma : a comparison of the circSCORE and the MCL35 score
(
- Contribution to journal › Article
-
Mark
HPV self-sampling versus healthcare provider collection on the effect of cervical cancer screening uptake and costs in LMIC : a systematic review and meta-analysis
(
- Contribution to journal › Article
-
Mark
Nationwide Assessment of Patient Trajectories in Mantle Cell Lymphoma : The Swedish MCL complete Project
(
- Contribution to journal › Article
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Secondary malignancies among mantle cell lymphoma patients
(
- Contribution to journal › Article
-
Mark
Evidence for distinct mechanisms of immune suppression in EBV-positive and EBV-negative Hodgkin lymphoma
(
- Contribution to journal › Article
- 2022
-
Mark
Advances in immune therapies in hematological malignancies
(
- Contribution to journal › Scientific review
-
Mark
Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma : The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience
(
- Contribution to journal › Article
-
Mark
Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen - a real world study on patients diagnosed in Sweden 2007-2017
(
- Contribution to journal › Letter
-
Mark
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma : results from a Nordic Lymphoma Group phase II trial
(
- Contribution to journal › Letter
-
Mark
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population-based study of 736 patients
(
- Contribution to journal › Article
-
Mark
Impact of comorbidity in older patients with peripheral T-cell lymphoma : an international retrospective analysis of 891 patients
(
- Contribution to journal › Article
-
Mark
High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis
(
- Contribution to journal › Article
-
Mark
Tackling Mantle Cell Lymphoma in Europe
(
- Contribution to journal › Article
-
Mark
Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission
(
- Contribution to journal › Article
-
Mark
The EHA Research Roadmap: Malignant Lymphoid Diseases
(
- Contribution to journal › Article
-
Mark
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
(
- Contribution to journal › Article
-
Mark
Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma : a study of younger patients from the MCL2 and MCL3 clinical trials
(
- Contribution to journal › Article
- 2021
-
Mark
How should we use ibrutinib in patients with mantle cell lymphoma?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Detailed Long-Term Follow-Up of Patients Who Relapsed after the Nordic Mantle Cell Lymphoma Trials : MCL2 and MCL3
(
- Contribution to journal › Article
-
Mark
Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival
(
- Contribution to journal › Article
-
Mark
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
(
- Contribution to journal › Article
-
Mark
EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma : Recommendations for the Second Phase of the COVID-19 Pandemic
(
- Contribution to journal › Scientific review
-
Mark
Myocardial infarction in diffuse large B-cell lymphoma patients – a population-based matched cohort study
(
- Contribution to journal › Article
-
Mark
Clinical characteristics and histopathological patterns of hodgkin lymphoma and treatment outcomes at a tertiary cancer center in ethiopia
(
- Contribution to journal › Article
-
Mark
ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden
(
- Contribution to journal › Article
-
Mark
Association between anthropometry and lifestyle factors and risk of B-cell lymphoma : An exposome-wide analysis
(
- Contribution to journal › Article
-
Mark
Detecting deviations from the efficacy and safety results of single-arm trials using real-world data : The case of a CAR-T cell therapy in B-cell lymphoma
2021) In Pharmacoepidemiology and Drug Safety(
- Contribution to journal › Article
-
Mark
Newly diagnosed and relapsed follicular lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2021) In Annals of oncology : official journal of the European Society for Medical Oncology 32(3). p.298-308(
- Contribution to journal › Article
-
Mark
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
(
- Contribution to journal › Article
-
Mark
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets
(
- Contribution to journal › Article
- 2020
-
Mark
Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition
(
- Contribution to journal › Article
-
Mark
Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century – a Swedish lymphoma register study
(
- Contribution to journal › Article
-
Mark
Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study
(
- Contribution to journal › Article
-
Mark
Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
National e-library for standardized chemotherapy regimens
(
- Contribution to journal › Letter
-
Mark
Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL
(
- Contribution to journal › Letter
-
Mark
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
(
- Contribution to journal › Article
-
Mark
Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women
(
- Contribution to journal › Article
-
Mark
An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement
(
- Contribution to journal › Article
-
Mark
Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk
(
- Contribution to journal › Article
- 2019
-
Mark
Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma : A Nordic Lymphoma Epidemiology Group Study
(
- Contribution to journal › Article
-
Mark
Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition
(
- Contribution to journal › Article
-
Mark
Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition
(
- Contribution to journal › Article
-
Mark
Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma : a Swedish lymphoma register study
(
- Contribution to journal › Article
-
Mark
Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study
2019) In British Journal of Haematology(
- Contribution to journal › Article
-
Mark
Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases
(
- Contribution to journal › Article
-
Mark
Follicular Lymphoma : Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs
(
- Contribution to journal › Article
-
Mark
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
(
- Contribution to journal › Article
-
Mark
Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?
(
- Contribution to journal › Article
- 2018
-
Mark
Ibrutinib versus temsirolimus : 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study
(
- Contribution to journal › Article
-
Mark
Body composition measurements and risk of hematological malignancies : A population-based cohort study during 20 years of followup
(
- Contribution to journal › Article
-
Mark
Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma
(
- Contribution to journal › Article
-
Mark
Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity
(
- Contribution to journal › Article
-
Mark
A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia
(
- Contribution to journal › Article
-
Mark
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
(
- Contribution to journal › Letter
-
Mark
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
(
- Contribution to journal › Article
-
Mark
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON) : A multicentre, open-label, single-arm, phase 2 trial
(
- Contribution to journal › Article
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
(
- Contribution to journal › Article
-
Mark
Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma : A critical assessment of the R-IPI, IPI, and NCCN-IPI
(
- Contribution to journal › Article
-
Mark
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Impact of comorbidity on survival in peripheral T-cell lymphomas : A Swedish Lymphoma Registry study
(
- Contribution to journal › Article
- 2017
-
Mark
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma
(
- Contribution to journal › Letter
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
(
- Contribution to journal › Article
-
Mark
Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.
(
- Contribution to journal › Article
-
Mark
Outcome of peripheral T-cell lymphoma in first complete remission : a Danish-Swedish population-based study
(
- Contribution to journal › Article
-
Mark
International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma
(
- Contribution to journal › Article
-
Mark
Newly diagnosed and relapsed mantle cell lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
(
- Contribution to journal › Article
-
Mark
The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma : A Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Targeting of B-cell receptor signalling in B-cell malignancies
(
- Contribution to journal › Scientific review
-
Mark
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
(
- Contribution to journal › Article
-
Mark
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
(
- Contribution to journal › Article
- 2016
-
Mark
Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma - A population-based Swedish Lymphoma Register study.
(
- Contribution to journal › Article
-
Mark
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
(
- Contribution to journal › Article
-
Mark
No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.
2016) In British Journal of Haematology(
- Contribution to journal › Article
-
Mark
Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4
(
- Contribution to journal › Article
-
Mark
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement : An international multicenter collaboration
(
- Contribution to journal › Article
-
Mark
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
(
- Contribution to journal › Article
-
Mark
Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma : a Swedish Lymphoma Registry study
(
- Contribution to journal › Article
-
Mark
Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma : a Nordic Lymphoma Group study
(
- Contribution to journal › Article
- 2015
-
Mark
Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer.
(
- Contribution to journal › Article
-
Mark
Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study
(
- Contribution to journal › Article